Europe Alzheimer's Disease Drug Pipeline Analysis
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure on the social and health-care systems of the region. There is an urgent need for developing curative or disease-modifying therapies to offset the upcoming Alzheimer’s disease epidemic.
“Europe Alzheimer’s Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process.
Following parameters for each drug profile in development phase are covered in “Europe Alzheimer’s Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 19
- Preclinical: 49
- Clinical: 1
- Phase-I: 25
- Phase-I/II: 2
- Phase-II: 26
- Phase-II/III: 2
- Phase-III: 5
- Preregistration: 2
- Marketed: 10
- Unknown: 1
2. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: UNKNOWN
2.1 Overview
2.2 Alzheimer’s Disease Drug Profile in Clinical Phase
3. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: RESEARCH
3.1 Overview
3.2 Alzheimer’s Disease Drug Profile in Clinical Phase
4. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: PRECLINICAL
4.1 Overview
4.2 Alzheimer’s Disease Drug Profile in Clinical Phase
5. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: CLINICAL
5.1 Overview
5.2 Alzheimer’s Disease Drug Profile in Clinical Phase
6. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: PHASE-I
6.1 Overview
6.2 Alzheimer’s Disease Drug Profile in Clinical Phase
7. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: PHASE-I/II
7.1 Overview
7.2 Alzheimer’s Disease Drug Profile in Clinical Phase
8. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: PHASE-II
8.1 Overview
8.2 Alzheimer’s Disease Drug Profile in Clinical Phase
9. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: PHASE-II/III
9.1 Overview
9.2 Alzheimer’s Disease Drug Profile in Clinical Phase
10. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: PHASE-III
10.1 Overview
10.2 Alzheimer’s Disease Drug Profile in Clinical Phase
11. ALZHEIMER’S DISEASE DRUG CLINICAL PHASE: PREREGISTRATION
11.1 Overview
11.2 Alzheimer’s Disease Drug Profile in Clinical Phase
12. MARKETED
12.1 Overview
12.2 Marketed Drug Profile
Each Drug Profile has Tables Representing Following Information:
- Alternate Names
- Originator & Owner
- Collaborator
- Technology Provider
- Licensee
- Highest Development Phase
- Indications
- Class
- Mechanism of Action
- ATC code
- Designated Brand Name & Orphan Designation
Alzheimers disease is an irreversible, neurodegenerative brain disease which is associated with a progressive decline in memory, thinking, language, and learning capacity (NIA, 2012). One of the most common causes of death among people above 60 years is observed to be Alzheimers disease across the world. While the global prevalence of dementia is approximately xx% in people above 60 years, in Europe this figure is xx%, which is higher than the global average.
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure on the social and health-care systems of the region. There is an urgent need for developing curative or disease-modifying therapies to offset the upcoming AD epidemic.
Market Overview
UK is one of the major markets for Alzeimer’s disease in the European region. In this country, the number of patients with dementia in 2012 was estimated at 800,000. It is expected that by 2021, this number would increase significantly to over a million. Approximately, xx people having Alzeimer’s disease are the younger generation. With the increasing aging society in Europe, the number of people with dementia has increased substantially over the years, both in absolute figures and as a percentage of overall population. This number is likely to increase dramatically in the next 5-10 years, which implies an increased financial burden on the society as a whole.
Among the 5 EU markets, including Germany and Spain the number of patients is expected to increase at an average growth rate of 2.59% and 2.xx%, respectively, over the next 5-10 years.
In terms of number of patients, Germany is expected to record the highest number of prevalent cases among the 5 EU countries, increasing from xx million cases in 2012 to xx million cases in 2022.
The major driver of growth in the Alzheimer’s disease drug market is expected to be the launches of the premium-priced disease-modifying therapies solanezumab (Eli Lilly’s anti-beta-amyloid monoclonal antibody) and Baxter’s IVIG product Gammagard/Kiovig through 2021. Along with other countries, Solanezumab, the first disease-modifying therapy, would be launched initially in France, Germany, Italy, Spain and the United Kingdom, which are the major pharmaceuticals markets. This drug is expected to be highly successful and obtain a blockbuster status in its first full year on the market, owing to its substantial price premium over other current agents.
Additionally, increasing rates of polypharmacy is expected to contribute to the growth of the drug market till 2022, as disease-modifying therapies would frequently be prescribed along with approved symptomatic agents, which will remain the mainstays of Alzeimer’s Disease treatment in order to achieve optimal clinical benefit. A rapidly growing drug-related population is expected to contribute to the expansion of the market through 2022. The increasing availability of amyloid-imaging agents would allow for earlier diagnosis of the disease. The use of these new and innovative diagnostic tools, combined with the greater efficacy that emerging therapies are expected to offer over current therapies, is expected to increase both diagnosis and drug-treatment rates across the regions.
Future Scenario
Many treatment strategies which could have potential capability to change the course of alzheimer’s disease is being currently researched in Europe and across the globe. There are close to 75 to 100 experimental therapies which are targeted at slowing or stopping the progression of AD, but these are still in clinical testing stage in human volunteers. It is most likely that in the future years to come, the treatments to slow or stop the progression of AD and preserve brain function would be most effective when administered early in the course of the disease, 10 years or more before symptoms appear. The current areas of research have been focussing on identifying biomarkers which would enable an early detection and inform physicians which patients should receive treatment during these very early stages of AD.
Currently, the Alzeimer’s disease treatment market includes only symptomatic therapies of reasonable efficacy which do not impact the progression of the disease. There is still no single treatment solution or combating the Alzeimer’s disease. However, the unsuccessful usage of potentially disease-modifying therapies in the last five years have encouraged the enthusiasm of many experts and have instigated them to initiate new and emerging therapies. It is expected that atleast by the next decade, an effective and safe disease-modifying therapy would be introduced to treat the patients suffering from Alzeimer’s disease.
However, it remains a fact that Alzheimer’s disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry owing to the significant and rapid increase in the number of patients and the growing frustration due to lack of effective treatments. Though many marketed drugs have been approved for AD, this remains a significant area of unmet medical need. Though many pharma players are developing novel treatment methods, the clinical success of these options has proven elusive, which throws open the market with huge potential.
